1 hr ago
Gilead Sciences: What Happened Today?
Now there are two possibilities. StreetInsider.com and the Fly On the Wall both referred to a voluntary recall of Gilead's HIV-drug Atripla , though both made referencer to a Deutsche Bank report that dismissed the recall as minor and unlikely to have a major impact.
Trending on the Topix Network
9 hrs ago
Biotech: What the Heck Happened?
Attributing a day's decline in stocks to "loss of momentum" is a bit like the undertaker who, standing over the corpse dumbfoundedly, says, "He died from loss of breath."
10 hrs ago
The Motley Fool
Better Biotech Buy: Celgene vs. Gilead Sciences
Each stock has gained more than 50% over the past year as these two companies surge behind older established cash cow drugs while putting their hopes behind ballyhooed new therapies in development and on the market.
Tue Mar 04, 2014
Gilead Prices $4 Billion of Senior Unsecured Notes
The offering is expected to close March 7, 2014, subject to customary closing conditions.
Mon Mar 03, 2014
Gilead Sciences CEO joins billionaires' ranks
That's how much Gilead Sciences CEO John Martin is worth, based on his stake in the Foster City company, which recently released a potential blockbuster drug to treat Hepatitis C. Sovaldi is among the first of a new wave of medicines that can cure the liver disease faster and more reliably than previous drugs.
Fri Feb 28, 2014
Gilead Sciences to Present at the 34th Cowen & Co. Healthcare Conference on Monday, March 3
Healthcare Conference in Boston. John F. Milligan, PhD, Gilead's President and Chief Operating Officer, will provide an overview of the company at the conference on Monday, March 3 at 2:10 p.m. Eastern Time.
Tue Feb 25, 2014
Gilead Sciences to Present at the RBC Capital Markets 2014 Global...
Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from the RBC Capital Markets 2014 Global Healthcare Conference in New York.
Fri Feb 21, 2014
The Motley Fool
Today's Top Stories in Biotech: Gilead Sciences, Isis Pharmaceuticals, and Opka Health Inc.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Thu Feb 20, 2014
The Motley Fool
Gilead Sciences, Inc on Its Way to Dominating Its Second Multibillion-Dollar Market
It's rare enough for a biotech to succeed, and even rarer for a biotech to ultimately dominate a therapeutic area.
Tue Feb 18, 2014
San Mateo Daily Journal
Foster City's drug giant: Gilead aims to increase access to medication with expanded campus
Foster City biopharmaceutical giant Gilead Science, Inc. is at forefront of discovering drugs to treat life-threatening diseases and its officials believe essentially doubling the size of its campus will allow it to expand its assistance to developing countries across the world.
Fri Feb 14, 2014
Gilead Sciences: Just How Good are Sovaldi's Sales?
Very, very good, says Citigroup's Yaron Werber and team, who expect Gilead Sciences sales of Sovaldi to blow away expectations.
Mon Feb 10, 2014
Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose...
Gilead Sciences, Inc. today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.
Investor's Business Daily
Gilead Sciences to Present at Two Upcoming Investor Conferences
Gilead Sciences, Inc. today announced that the company will be webcasting its corporate presentation at two upcoming investor conferences: the 16th Annual BIO CEO & Investor Conference and the 2014 Leerink Swann Healthcare Conference, both taking place in New York.
Thu Feb 06, 2014
The Motley Fool
Reflections on the Biotech Earnings Bonanza: LLY, NVO, GILD
Biotech earnings season is now in full swing. As I highlighted in my last article , I think it's key to think globally in terms of the sector's growth prospects.
Wed Feb 05, 2014
Gilead Sciences Given "Buy" Rating at Deutsche Bank
's stock had its "buy" rating restated by investment analysts at Deutsche Bank in a note issued to investors on Wednesday, American Banking and Market News reports.
Gilead Drops as Sovaldi Optimism Turns to Pessimism
Gilead Sciences delivered the goods last night when it reported its results. Today, however, the market is focused on the biotech companies forecast, which didn't include projections for its new Hepatitis-C drug.